Antiangiogenic therapy for high-grade gliomas

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 3, 2009, Pages 184-194

  Chamberlain, Marc C ^a   Raizer, Jeff ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiangiogenic therapy; High grade gliomas

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; IRINOTECAN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE MARKER; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; EPISTAXIS; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LUNG EMBOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL BLEEDING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION RESPONSE; RECURRENT CANCER; REVIEW; TUMOR BLEEDING; TUMOR VASCULARIZATION; TUMOR VOLUME; VAGINA BLEEDING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

EID: 70349620987     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709788680706     Document Type: Review

References (129)

1. Intergroup Radiation Therapy Oncology Group Trial 9402; Cairncross, G.; Berkey, B.; Shaw, E.; Jenkins, R.; Scheithauer, B.; Brachman, D.; Buckner, J.; Fink, K.; Souhami, L.; Laperierre, N.; Mehta, M.; Curran, W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma. J. Clin. Oncol., 2006, 24(18), 2707-14.
2. Mischel, P.; Shai, R.; Shi, T.; Horvath, S.; Lu, K.V.; Choe, G.; Seligson, D.; Kremen, T.J.; Palotie, A.; Liau, L.M.; Cloughesy, T.F.; Nelson, S.F. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene, 2003, 22(15), 2361-73.
3. Reardon, D.A.; Wen, P.Y.; Desjardins, A.; Batchelor, T.T.; Vredenburgh, J.J. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin. Biol. Ther., 2008, 8(4), 541-53.
4. Rich, J.; Hans, C.; Jones, B.; Iversen, E.S.; McLendon, R.E.; Rasheed, B.K.; Dobra, A.; Dressman, H.K.; Bigner, D.D.; Nevins, J.R.; West, M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res., 2005, 65(10), 4051-8.
5. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Group; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352, 987-96.
6. van den Bent, M.J.; Carpentier, A.F.; Brandes, A.A.; Sanson, M.; Taphoorn, M.J.; Bernsen, H.J.; Frenay, M.; Tijssen, C.C.; Grisold, W.; Sipos, L.; Haaxma-Reiche, H.; Kros, J.M.; van Kouwenhoven, M.C.; Vecht, C.J.; Allgeier, A.; Lacombe, D.; Gorlia, T. Adjuvant procarbazine, lomustine and vincristine improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol., 2006, 24(18), 2715-22.
7. Stark-Vance, V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol., 2005, 7(3), 369 (abstract).
8. Pope, W.B.; Lai, A.; Nghiemphu, P. Mischel, P.; Cloughesy, T.F. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology, 2006, 66(8), 1258-60.
9. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., II; Dowell, J.M.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res., 2007, 13(4),1253-9.
10. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., 2nd; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol., 2007, 25(30), 4722-9.
11. Chen, W.; Delaloye, S.; Silverman, D.H.; Geist, C.; Czernin, J.; Sayre, J.; Satyamurthy, N.; Pope, W.; Lai, A.; Phelps, M.E.; Cloughesy, T.F. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol., 2007, 25(30), 4714-21.
12. Norden, A.D.; Young, G.S.; Setayesh, K.; Muzikansky, A.; Klufas, R.; Ross, G.L.; Ciampa, A.S.; Ebbeling, L.G.; Levy, B.; Drappatz, J.; Kesari, S.; Wen, P.Y. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology, 2008, 70(10), 779-87.
13. Cloughesy, T.; Prados, M.D.; Mikkelsen, T. A phase II randomized non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan on 6-month progression free survival in recurrent treatment refractory glioblastoma. J. Clin. Oncol., 2008, 26, 91s.
14. Bergers, G.; Benjamin, L. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer, 2003, 3(6), 401-10.
15. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature, 2005, 43, 932-6.
16. Fischer, I.; Gagner, J.P.; Law, M.; Newcomb, E.W.; Zagzag, D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol., 2005, 15(4), 297-310.
17. Folkman J. Angiogenesis. Ann. Rev. Med., 2006, 57, 1-18.
18. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-64.
19. Jain, R.K.; di Tomaso, E.; Duda, D.G.; Loeffler, J.S.; Sorensen, A.G.; Batchelor, T.T. Angiogenesis in brain tumors. Nat. Rev. Neurosci., 2007, 8, 610-22.
20. Kargiotis, O.; Rao, J.S.; Kyritsis, A.P. Mechanisms of angiogenesis in gliomas. J. Neurooncol., 2006, 78(3), 281-93.
21. Kerbel, R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science, 2006, 312(5777), 1171-5.
22. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med., 2008, 358(19), 2039-49.
23. Plate, K.H.; Risau, W. Angiogenesis in malignant gliomas. Glia, 1995, 15(3), 339-47.
24. Semenza, G.L. A new weapon for attaching tumor blook vessels. N. Engl. J. Med., 2008, 358(19), 2066-7.
25. Bertolini, F.; Shakeci, Y.; Mancuso, P.; Kerbel, R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer, 2006, 6, 835-45.
26. Fürstenberger, G.; von Moos, R.; Lucas, R.; Thürlimann, B.; Senn, H.J.; Hamacher, J.; Boneberg, E.M. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer, 2006, 94, 524-31.
27. Gao, D.; Nolan, D.J.; Mellick, A.S.; Bambino, K.; McDonnell; K.; Mittal, V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science, 2008, 319, 195-8.
28. Nolan, D.J.; Ciarrocchi, A.; Mellick, A.S.; Jaggi, J.S.; Bambino, K.; Gupta, S.; Heikamp, E.; McDevitt, M.R.; Scheinberg, D.A.; Benezra, R.; Mittal, V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev., 2007, 21, 1546-58.
29. Rafii, S.; Lyden, D.; Benezra, R.; Hattori, K.; Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer, 2002, 2, 826-35.
30. Rajantie, I.; Ilmonen, M.; Alminaite, A.; Ozerdem, U.; Alitalo, K.; Salven, P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood, 2004, 104(7), 2084-6.
31. Santarelli, J.G.; Udani, V.; Yung, C.Y.; Cheshier, S.; Wagers, A.; Brekken, R.A.; Weissman, I.; Tse, V. Preuss resident research award: bone marrow-derived Flk-1-expressing CD34+ cells contribute to the endothelium of tumor vessels in mouse brain. Clin. Neurosurg., 2005, 52, 384-8.
32. Zheng, P.P.; Hop, W.C.; Luider, T.M.; Sillevis S.P.A.; Kros, J.M. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann. Neurol., 2007, 62, 40-8.
33. Peters, B.A.; Diaz, L.A.; Polyak, K.; Meszler, L.; Romans, K.; Guinan, E.C.; Antin, J.H.; Myerson, D.; Hamilton, S.R.; Vogelstein, B.; Kinzler, K.W.; Lengauer, C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med., 2005, 11(3), 261-2.
34. Holash, J.; Maisonpierre, P.C.; Compton, D.; Boland, P.; Alexander, C.R.; Zagzag, D.; Yancopoulos, G.D.; Wiegand, S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999, 284(5422), 1994-8.
35. Leenders, W.P.; Küsters, B.; Verrijp, K.; Maass, C.; Wesseling, P.; Heerschap, A.; Ruiter, D.; Ryan, A.; de Waal, R. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res., 2004, 10(18 pt 1), 6222-30.
36. Rong, V.; Durden, D.L.; Van Meir, E.G.; Brat, D.J. Pseudopalisading necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol., 2006, 65, 529-39.
37. Abounader, R.; Laterra, J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neurooncology, 2005, 7(4), 436-51.
38. Bao, S.; Wu, Q.; Sathornsumetee, S.; Hao, Y.; Li, Z.; Hjelmeland, A.B.; Shi, Q.; McLendon, R.E.; Bigner, D.D.; Rich, J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res., 2006, 66(16), 7843-8.
39. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-76.
40. Ferrara, N. VEGF as a therapeutic target in cancer. Oncology, 2005, 69(Suppl 3), 11-6.
41. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; de Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J.M.; Dewerchin, M.; Collen, D.; Carmeliet, P. Anti-PIGF inhibits growth of VEGF®-inhibitor-resistant tumors without affecting healthy vessels. Cell, 2007, 131(3), 463-75.
42. Hicklin, D.J.; Elis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and antiangiogenesis. J. Clin. Oncol., 2005, 23, 1011-27.
43. Jain, R.K.; Safabakhsh, N.; Sckell, A.; Chen, Y.; Jiang, P.; Benjamin, L.; Yuan, F.; Keshet, E. Endothelial cell death, angiogenesis and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA, 1998, 95, 10820-5.
44. Jain, R.K.; Xu, L. αPIGF: a new kid on the antiangiogenesis block. Cell, 2007, 131, 443-5.
45. Kowanerz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res., 2006, 12(17), 5018-22.
46. Kunkel, P.; Ulbricht, U.; Bohlen, P.; Brockmann, M.A.; Fillbrandt, R.; Stavrou, D.; Westphal, M.; Lamszus, K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res., 2001, 61(18), 6624-8.
47. Plate, K.H.; Breier, G.; Millaauer, B.; Ullrich, A.; Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res., 1993, 53(23), 5822-7.
48. Kaur, B.; Khwaja, F.W.; Severson, E.A.; Matheny, S.L.; Brat, D.J.; Van Meir, E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. J. Neurooncol., 2005, 7(2), 134-53.
49. Kaur, B.; Tan, C.; Brat, D.J.; Post, D.E.; Van Meir, E.G. Genetic and hypoxic regulation of angiogenesis in gliomas. J. Neurooncol., 2004, 70(2), 229-43.
50. Zagzag, D.; Zhong, H.; Scalzitti, J.M.; Laughner, E.; Simons, J.W.; Semenza, G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer, 2000, 88(11), 2606-18.
51. Chi, A.; Norden, A.D.; Wen, P.Y. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev. Anticancer Ther., 2007, 7(11), 1537-60.
52. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I.T.; Zakharenko, S.S.; Gajjar, A.; Davidoff, A.; Gilbertson, R.J. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11(1), 69-82.
53. Duda, D.G.; Jain, R.K.; Willett, C.G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol., 2007, 25(26), 4033-42.
54. Gilbertson, R.J.; Rich, J.N. Making a tumour's bed: gliobastoma stem cells and the vascular niche. Nat. Rev. Cancer, 2007, 7(10), 733-6.
55. Gorski, D.H.; Beckett, M.A.; Jaskowiak, N.T.; Calvin, D.P.; Mauceri, H.J.; Salloum, R.M.; Seetharam, S.; Koons, A.; Hari, D.M.; Kufe, D.W.; Weichselbaum, R.R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res., 1999, 59(14), 3374-8.
56. Tong, R.T.; Boucher, Y.; Kozin, S.V.; Winkler, F.; Hicklin, D.J.; Jain, R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res., 2004, 64(11), 3731-6.
57. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med., 2001, 7(9), 987-9.
58. Jain, R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307(5706), 58-62.
59. Lamszus, K.; Heese, O.; Westphal, M. Angiogenesis-related growth factors in brain tumors. Cancer Treat. Res., 2004, 117, 169-90.
60. Pore, N.; Liu, S.; Haas-Kogan, D.A.; O'Rourke, D.M.; Maity, A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res., 2003, 63(1), 236-41.
61. Samoto, K.; Ikezaki, K.; Ono, M.; Shono, T.; Kohno, K.; Kuwano, M.; Fukui, M. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res., 1995, 55(5), 1189-93.
62. Schmidt, N.O.; Westphal, M.; Hagel, C.; Ergün, S.; Stavrou, D.; Rosen, E.M.; Lamszus, K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer, 1999, 84(1), 10-18.
63. Tuettenberg, J.; Friedel, P.; Vajkoczy, P. Angiogenesis in malignant glioma-a target for antitumor therapy? Crit. Rev. Oncol. Hematol., 2006, 59, 181-93.
64. Salmaggi, A.; Eoli, M.; Frigerio, S.; Silvani, A.; Gelati, M.; Corsini, E.; Broggi, G.; Boiardi, A. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J. Neurooncol., 2003, 62, 297-303.
65. Bao, S.; Wu, Q.; McLendon, R.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120), 687-8.
66. Folkins, C.; Man, S.; Xu, P.; Shaked, Y.; Hicklin, D.J.; Kerbel, R.S. Anticancer therapies combining antiangiogenic and tumor cell cytoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res., 2007, 67(8), 3560-4.
67. Fomchenko, E.I.; Holland, E.C. Origins of brain tumors - a disease of stem cells? Nat. Clin. Pract. Neurol., 2006, 2, 288-9.
68. Purow, B.; Fine, H.A. Antiangiogenic therapy for primary and metastatic brain tumors. Hematol. Oncol. Clin. N. Am., 2004, 18, 1161-81.
69. Stefanik, D.F.; Fellows, W.K.; Rizkalla, L.R.; Stefanik, P.P.; Deleo, A.B.; Welch, W.C. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol., 2001, 55(2), 91-100.
70. Stefanik, D.F.; Rizkalla, L.R.; Soi, A.; Goldblatt, S.A.; Rizkalla, W.M. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res., 1991, 51(20), 5760-5.
71. Sun, L.; Hui, A.M.; Su, Q.; Vortmeyer, A.; Kotliarov, Y.; Pastorino, S.; Passaniti, A.; Menon, J.; Walling, J.; Bailey, R.; Rosenblum, M.; Mikkelsen, T.; Fine, H.A. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell, 2006, 9(4), 287-300.
72. Weis, S.M.; Cheresh, D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature, 2005, 437, 497-504.
73. Winkler, F.; Kozin, S.V.; Tong, R.; Chae, S.; Booth, M.F.; Garkavtsev, I.; Xu, L.; Hicklin, D.J.; Fukumura, D.; di Tomaso, E.; Munn, L.L.; Jain, R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation angiopoietin-1 and matrix metalloproteinases. Cancer Cell, 2004, 6(6), 553-63.
74. Batchelor, T.T.; Sorensen, A.G.; di Tomaso, E.; Zhang, W.T.; Duda, D.G.; Cohen, K.S.; Kozak, K.R.; Cahill, D.P.; Chen, P.J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M.M.; Plotkin, S.; Drappatz, J.; Louis, D.N.; Ivy, P.; Scadden, D.T.; Benner, T.; Loeffler, J.S.; Wen, P.Y.; Jain, R.K. AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007, 11(1), 83-95.
75. Cobleigh, M.A.; Langmuir, V.K.; Sledge, G.W.; Miller, K.D.; Haney, L.; Novotny, W.F.; Reimann, J.D.; Vassel, A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol., 2003, 30(5 Suppl 16), 117-24.
76. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-42.
77. Jain, R.K.; Duda, D.G.; Clark, J.W.; Loeffler, J.S. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol., 2006, 3(1), 24-40.
78. Kindler, H.L.; Friberg, G.; Singh, D.A.; Locker, G.; Nattam, S.; Kozloff, M.; Taber, D.A.; Karrison, T.; Dachman, A.; Stadler, W.M.; Vokes, E.E. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 2005, 23(31), 8033-40.
79. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355(24), 2542-50.
80. Wedam, S.B.; Low, J.A.; Yang, S.X.; Chow, C.K.; Choyke, P.; Danforth, D.; Hewitt, S.M.; Berman, A.; Steinberg, S.M.; Liewehr, D.J.; Plehn, J.; Doshi, A.; Thomasson, D.; McCarthy, N.; Koeppen, H.; Sherman, M.; Zujewski, J.; Camphausen, K.; Chen, H.; Swain, S.M. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breat cancer. J. Clin. Oncol., 2006, 24(5), 769-77.
81. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozon, S.V.; Mino, M.; Cohen, K.S.; Scadden, D.T.; Hartford, A.C.; Fischman, A.J.; Clark, J.W.; Ryan, D.P.; Zhu, A.X.; Blaszkowsky, L.S.; Chen, H.X.; Shellito, P.C.; Lauwers, G.Y.; Jain, R.K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004, 10(2), 145-7.
82. Yang, J.C.; Haworth, L.; Sherry, R.M.; Hwu, P.; Schwartzentruber, D.J.; Topalian, S.L.; Steinberg, S.M.; Chen, H.X.; Rosenberg, S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med., 2003, 349(5), 427-34.
83. Yung, W.K.; Albright, R.E.; Olson, J.; Fredericks, R.; Fink, K.; Prados, M.D.; Brada, M.; Spence, A.; Hohl, R.J.; Shapiro, W.; Glantz, M.; Greenberg, H.; Selker, R.G.; Vick, N.A.; Rampling, R.; Friedman, H.; Phillips, P.; Bruner, J.; Yue, N.; Osoba, D.; Zaknoen, S.; Levin, V.A. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer, 2000, 83(5), 588-93.
84. Wong, E.T.; Hess, K.R.; Gleason, M.J.; Jaeckle, K.A.; Kyritsis, A.P.; Prados, M.D.; Levin, V.A.; Yung, W.K. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol., 1999, 17(8), 2572-8.
85. Eremina, V.; Jefferson, J.A.; Kowalewska, J. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med., 2008, 358(11), 1129-36.
86. Eskens, F.A.; Verweij, J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: a review. Eur. J. Cancer, 2006, 42, 3127-39.
87. Verheul, H.M.; Pinedo, H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer, 2007, 7, 475-85.
88. Brandes, A.A.; Scelzi, E.; Salmistraro, G.; Ermani, M.; Carollo, C.; Berti, F.; Zampieri, P.; Baiocchi, C.; Fiorentino, M.V. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur. J. Cancer, 1997, 33(10), 1592-6.
89. Marras, L.C.; Geerts, W.H.; Perry, J.R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer, 2000, 89, 640-6.
90. Semrad, T.J.; O'Donnell, R.; Wun, T.; Chew, H.; Harvey, D.; Zhou, H.; White, R.H. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J. Neurosurg., 2007, 106(4), 601-8.
91. Simanek, R.; Vormittag, R.; Hassler, M.; Roessler, K.; Schwarz, M.; Zielinski, C.; Pabinger, I.; Marosi, C. Venous thromboembolism and survival in patients with high-grade glioma. Neuro-Oncol., 2007, 9(2), 89-95.
92. Chamberlain, M.C. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J. Neurooncol., 2002, 56, 183-8.
93. Friedman, H.S.; Petros, W.P.; Friedman, A.H.; Schaaf, L.J.; Kerby, T.; Lawyer, J.; Parry, M.; Houghton, P.J.; Lovell, S.; Rasheed, K.; Cloughsey, T.; Stewart, E.S.; Colvin, O.M.; Provenzale, J.M.; McLendon, R.E.; Bigner, D.D.; Cokgor, I.; Haglund, M.; Rich, J.; Ashley, D.; Malczyn, J.; Elfring, G.L.; Miller, L.L. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol., 1999, 17(5), 1516-25.
94. Casanovas, O.; Hicklin, D.J.; Bergers, G.; Hananhan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 2005, 8, 299-309.
95. Giese, A.; Bjerkvig, R.; Berens, M.E.; Westphal, M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol., 2003, 21(8), 1624-36.
96. Huang, J.; Soffer, S.Z.; Kim, E.S.; McCrudden, K.W.; Huang, J.; New, T.; Manley, C.A.; Middlesworth, W.; O'Toole, K.; Yamashiro, D.J.; Kandel, J.J. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res., 2004, 2(1), 36-42.
97. Kerbel, R.; Yu, J.; Tran, J.; Man, S.; Viloria-Petit, A.; Klement, G.; Coomber, B.L.; Rak, J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev., 2001, 20(1-2), 79-86.
98. Lamszus, K.; Kunkel, P.; Westphal, M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl., 2003, 88, 169-77.
99. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol., 2005, 23(10), 2411-22.
100. Miller, K.D.; Sweeney, C.J.; Sledge, G.W.; Jr. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann. Oncol., 2003, 14, 20-28.
101. Nakada, M.; Nakada, S.; Demuth, T.; Tran, N.L.; Hoelzinger, D.B.; Berens, M.E. Molecular targets of glioma invasion. Cell Mol. Life Sci., 2007, 64(4), 458-78.
102. Rao, J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer, 2003, 3(7), 489-501.
103. Rubenstein, J.L.; Kim, J.; Ozawa, T.; Zhang, M.; Westphal, M.; Deen, D.F.; Shuman, M.A. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia, 2000, 2(4), 306-14.
104. Sakariassen, P.O.; Prestegarden, L.; Wang, J.; Skaftnesmo, K.O.; Mahesparan, R.; Molthoff, C.; Sminia, P.; Sundlisaeter, E.; Misra, A.; Tysnes, B.B.; Chekenya, M.; Peters, H.; Lende, G.; Kalland, K.H.; Øyan, A.M.; Petersen, K.; Jonassen, I.; van der Kogel, A.; Feuerstein, B.G.; Terzis, A.J.; Bjerkvig, R.; Enger, P.Ø. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc. Natl. Acad. Sci. USA, 2006, 103(44), 16466-71.
105. Salhia, B.; Tran, N.L.; Symons, M.; Winkles, J.A.; Jutka, J.T.; Berens, M.E. Molecular pathways triggering glioma cell invasion. Expert Rev. Mol. Diagn., 2006, 6(4), 613-26.
106. Shojaei, F.; Wu, X.; Malik, A.K.; Zhong, C.; Baldwin, M.E.; Schanz, S.; Fuh, G.; Gerber, H.P.; Ferrara, N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol., 2007, 25(8), 911-20.
107. Sweeney, C.; Miller, K.; Sledge, G.J. Resistance in the antiangiogenic era: nay-saying or a word of caution? Trends Mol. Med., 2003, 9(1), 24-9.
108. Cha, S.; Yang, L.; Johnson, G.; Lai, A.; Chen, M.H.; Tihan, T.; Wendland, M.; Dillon, W.P. Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. Am. J. Neuroradiol., 2006, 27(2), 409-17.
109. Henson, J.W.; Ulmer, S.; Harris, G.J. Brain tumor imaging in clinical trials. Am. J. Neuroradiol., 2008, 29(3), 419-24.
110. Jackson, A.; O'Connor, J.P.; Parker, G.J.; Jayson, G.C. Imaging rumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin. Cancer Res., 2007, 12(12), 3449-59.
111. Hylton, N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J. Clin. Oncol., 2006, 24(20), 3293-8.
112. Carlson, M.R.; Pope, W.B.; Horvath, S.; Braunstein, J.G.; Nghiemphu, P.; Tso, C.L.; Mellinghoff, I.; Lai, A.; Liau, L.M.; Mischel, P.S.; Dong, J.; Nelson, S.F.; Cloughesy, T.F. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin. Cancer Res., 2007, 13(9), 2592-8.
113. Davis, D.W.; McConkey, D.J.; Abbruzzese, J.L.; Herbst, R.S. Surrogate markers in antiangiogenesis clinical trials. Br. J. Cancer, 2003, 89, 8-14.
114. Jubb, A.M.; Oates, A.J.; Holden, S.; Koeppen, H. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer, 2006, 6, 626-35.
115. Leon, S.P.; Folkerth, R.D.; Black, P.M. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer, 1996, 77(2), 362-72.
116. Willett, C.G.; Boucher, Y.; Duda, D.G.; di Tomaso, E.; Munn, L.L.; Tong, R.T.; Kozin, S.V.; Petit, L.; Jain, R.K.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Cohen, K.S.; Scadden, D.T.; Fischman, A.J.; Clark, J.W.; Ryan, D.P.; Zhu, A.X.; Blaszkowsky, L.S.; Shellito, P.C.; Mino-Kenudson, M.; Lauwers, G.Y. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol., 2005, 23(31), 8136-9.
117. Aldape, K.D.; Ballman, K.; Furth, A.; Buckner, J.C.; Giannini, C.; Burger, P.C.; Scheithauer, B.W.; Jenkins, R.B.; James, C.D. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J. Neuropathol. Exp. Neurol., 2004, 63(7), 700-7.
118. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 2000, 343(19), 1350-4.
119. Freije, W.; Castro-Vargas, F.; Fang, Z.; Horvath, S.; Cloughesy, T.; Liau, L.M.; Mischel, P.S.; Nelson, S.F. Gene expression profiling of gliomas strongly predicts survival. Cancer Res., 2004, 64(18), 6503-10.
120. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352(10), 997-1003.
121. Liang, Y.; Diehn, M.; Watson, N.; Bollen, A.W.; Aldape, K.D.; Nicholas, M.K.; Lamborn, K.R.; Berger, M.S.; Botstein, D.; Brown, P.O.; Israel, M.A. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. USA, 2005, 102(16), 5814-9.
122. Maher, E.; Brennan, C.; Wen, P.; Durso, L.; Ligon, K.L.; Richardson, A.; Khatry, D.; Feng, B.; Sinha, R.; Louis, D.N.; Quackenbush, J.; Black, P.M.; Chin, L.; DePinho, R.A. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res., 2006, 66(23), 11502-13.
123. Mellinghoff, I.K.; Wang, M.Y.; Vivanco, I.; Haas-Kogan, D.A.; Zhu, S.; Dia, E.Q.; Lu, K.V.; Yoshimoto, K.; Huang, J.H.; Chute, D.J.; Riggs, B.L.; Horvath, S.; Liau, L.M.; Cavenee, W.K.; Rao, P.N.; Beroukhim, R.; Peck, T.C.; Lee, J.C.; Sellers, W.R.; Stokoe, D.; Prados, M.; Cloughesy, T.F.; Sawyers, C.L.; Mischel, P.S. Molecule determinants of the response of glioblastomas to EGRF kinase inhibitors. N. Engl. J. Med., 2005, 353(19), 2012-24.
124. Shai, R.; Shi, T.; Kremem, T.J.; Horvath, S.; Liau, L.M.; Cloughesy, T.F.; Mischel, P.S.; Nelson, S.F. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene, 2003, 22(31), 4918-23.
125. Tso, C.; Freije, W.; Day, A.; Chen, Z.; Merriman, B.; Perlina, A.; Lee, Y.; Dia, E.Q.; Yoshimoto, K.; Mischel, P.S.; Liau, L.M.; Cloughesy, T.F.; Nelson, S.F. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res., 2006, 66(1), 159-67.
126. 18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin. Cancer Res., 2008, 14(9), 2623-30.
127. Sathornsumetee, S.; Cao, Y.; Marcello, J.E.; Herndon, J.E., 2nd; McLendon, R.E.; Desjardins, A.; Friedman, H.S.; Dewhirst, M.W.; Vredenburgh, J.J.; Rich, J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol., 2008, 26(2), 271-8.
128. Raizer, J.J.; Grimm, S.; Rice, L.; Muro, K.; Chandler, J.; Tellez, C.; Mellot, A.L.; Newman, S.; Nicholas, M.K.; Chamberlain, M.C. A phase II trial of single agent bevacizumab given every 3 weeks for recurrent malignant gliomas. Proc. Am. Soc. Clin. Oncol., 2009.
129. Kreisl, T.N.; Kim, L.; Moore, K.; Duic, P.; Royce, C.; Stroud, I.; Garren, N.; Mackey, M.; Butman, J.A.; Camphausen, K.; Park, J.; Albert, P.S.; Fine, H.A. Phase II trial of single agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol., 2009, 27, 1-10.